Great to have Chris leading the company he is so experienced with plenty of commitment holding a massive ... 2,527,798 shares
“Dr Burns has over 30 years’ experience in drug discovery and development and has served in executive level positions, including as CEO, for a number of public and private biotechnology companies. Dr Burns’ deep experience in cancer biology and kinase inhibitor development has contributed to advancement of multiple clinical candidates and he was the lead inventor of the drug momelotinib, a Janus kinase (JAK) inhibitor targeting myelofibrosis, which was recently acquired by GSK for US$1.9billion.”
Looking forward to regular updates / video interviews
And a little snippet telling us how the trails are going
Would do the trick nicely ...
.
ATX Price at posting:
9.9¢ Sentiment: Buy Disclosure: Held
